Neurocrine Biosciences Inc NBIX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
142.29UNCH (UNCH)
Volume
26,909
Close
142.29quote price arrow up+0.38 (+0.27%)
Volume
615,028
52 week range
89.04 - 148.37
Loading...
  • Open141.97
  • Day High142.86
  • Day Low140.51
  • Prev Close141.91
  • 52 Week High148.37
  • 52 Week High Date03/21/24
  • 52 Week Low89.04
  • 52 Week Low Date05/30/23

Key Stats

  • Market Cap14.32B
  • Shares Out100.64M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta0.37
  • YTD % Change7.99

KEY STATS

  • Open141.97
  • Day High142.86
  • Day Low140.51
  • Prev Close141.91
  • 52 Week High148.37
  • 52 Week High Date03/21/24
  • 52 Week Low89.04
  • 52 Week Low Date05/30/23
  • Market Cap14.32B
  • Shares Out100.64M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta0.37
  • YTD % Change7.99

RATIOS/PROFITABILITY

  • EPS (TTM)3.64
  • P/E (TTM)39.10
  • Fwd P/E (NTM)30.97
  • EBITDA (TTM)492.90M
  • ROE (TTM)18.16%
  • Revenue (TTM)1.982B
  • Gross Margin (TTM)98.05%
  • Net Margin (TTM)18.65%
  • Debt To Equity (MRQ)5.15%

EVENTS

  • Earnings Date07/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Neurocrine Biosciences Inc

Profile

MORE
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline...
William Rastetter Ph.D.
Non-Executive Independent Chairman of the Board
Kevin Gorman Ph.D.
Chief Executive Officer, Director
Matthew Abernethy CPA
Chief Financial Officer
Address
6027 EDGEWOOD BEND COURT
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
MEDP
Medpace Holdings Inc
393.30+0.02+0.01%
SRPT
Sarepta Therapeutics Inc
131.38-1.36-1.02%
NTRA
Natera Inc
106.46-2.04-1.88%
ALNY
Alnylam Pharmaceuticals Inc
149.40-1.82-1.20%
EXAS
Exact Sciences Corp
50.38-1.57-3.02%